{"title":"LHRH类似物治疗晚期胰腺癌患者。初步报告。","authors":"A Andrén-Sandberg","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Ten patients with non-extirpable adenocarcinoma of the pancreas received monthly subcutaneous implantations of the LHRH analogue goserelin. Subjective improvement (diminished abdominal pain and/or weight gain) occurred within 3 months in seven patients and persisted until about 2 months before death. The treatment was well tolerated by the patients. This preliminary study seems to warrant further investigation of goserelin in the management of pancreatic cancer.</p>","PeriodicalId":7005,"journal":{"name":"Acta chirurgica Scandinavica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1990-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment with an LHRH analogue in patients with advanced pancreatic cancer. A preliminary report.\",\"authors\":\"A Andrén-Sandberg\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Ten patients with non-extirpable adenocarcinoma of the pancreas received monthly subcutaneous implantations of the LHRH analogue goserelin. Subjective improvement (diminished abdominal pain and/or weight gain) occurred within 3 months in seven patients and persisted until about 2 months before death. The treatment was well tolerated by the patients. This preliminary study seems to warrant further investigation of goserelin in the management of pancreatic cancer.</p>\",\"PeriodicalId\":7005,\"journal\":{\"name\":\"Acta chirurgica Scandinavica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1990-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta chirurgica Scandinavica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta chirurgica Scandinavica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Treatment with an LHRH analogue in patients with advanced pancreatic cancer. A preliminary report.
Ten patients with non-extirpable adenocarcinoma of the pancreas received monthly subcutaneous implantations of the LHRH analogue goserelin. Subjective improvement (diminished abdominal pain and/or weight gain) occurred within 3 months in seven patients and persisted until about 2 months before death. The treatment was well tolerated by the patients. This preliminary study seems to warrant further investigation of goserelin in the management of pancreatic cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
